Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
– Based on a novel human cytomegalovirus vector platform, VIR-1388 was designed with the goal of creating a novel HIV...